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HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Platelet activation in cystic fibrosis
Brian P. O’Sullivan, Matthew D. Linden, Andrew L. Frelinger III, Marc R. Barnard, Michele Spencer-Manzon, James E. Morris,
Raneem O. Salem, Michael Laposata, and Alan D. Michelson
Cystic fibrosis (CF) is caused by a muta-
tion of the gene encoding the cystic
fibrosis transmembrane conductance
regulator (CFTR). We examined platelet
function in CF patients because lung
inflammation is part of this disease and
platelets contribute to inflammation. CF
patients had increased circulating leuko-
cyte-platelet aggregates and increased
platelet responsiveness to agonists
compared with healthy controls. CF
plasma caused activation of normal and
CF platelets; however, activation was
greater in CF platelets. Furthermore,
washed CF platelets also showed in-
creased reactivity to agonists. CF plate-
let hyperreactivity was incompletely in-
hibited by prostaglandin E1 (PGE1). As
demonstrated by Western blotting and
reverse-transcriptase–polymerase chain
reaction (RT-PCR), there was neither
CFTR nor CFTR-specific mRNA in nor-
mal platelets. There were abnormalities
in the fatty acid composition of mem-
brane fractions of CF platelets. In sum-
mary, CF patients have an increase in
circulating activated platelets and plate-
let reactivity, as determined by mono-
cyte-platelet aggregation, neutrophil-
platelet aggregation, and platelet surface
P-selectin. This increased platelet acti-
vation in CF is the result of both a
plasma factor(s) and an intrinsic plate-
let mechanism via cyclic adenosine
monophosphate (cAMP)/adenylate cy-
clase, but not via platelet CFTR. Our
findings may account, at least in part,
for the beneficial effects of ibuprofen in
CF. (Blood. 2005;105:4635-4641)
© 2005 by The American Society of Hematology
Introduction
Cystic fibrosis (CF) is the most common lethal genetic disease in
whites, affecting approximately 1 in 2500 live births.1 In 1989,
Kerem et al2; Riordan et al3; and Rommens et al4 identified the
genetic mutation responsible for CF and cloned its protein
product, which is called the cystic fibrosis transmembrane
conductance regulator (CFTR). CFTR is a member of the
adenosine triphosphate (ATP)–binding cassette family of trans-
porters and acts chiefly as a chloride channel, although it has
various other functions including regulation of alternate chlo-
ride channels and epithelial sodium channels, and transport
of ATP.5-7
Defects in CFTR cause reduced chloride secretion into airways
and enhanced sodium reabsorption, thereby resulting in dehydrated
airway secretions, poor mucociliary clearance, and airway obstruc-
tion.1 Obstruction of the airways, along with poorly understood
altered host defense mechanisms and an enhanced inflammatory
response, leads to chronic airway infection and inflammation. This,
in turn, causes an influx of polymorphonuclear cells that, when they
become senescent and release their DNA into the airway mucous,
contribute to thickening of airway secretions.8 The self-perpetuat-
ing cycle of obstruction, infection, and inflammation eventually
causes pulmonary parenchymal destruction and respiratory failure.
The life expectancy for CF patients in the United States is currently
approximately 33 years.9
Previous studies have shown that CF patients have increased ex
vivo platelet aggregability, increased release of thromboxane A2
(TXA2),10-12 and a blunted response to prostaglandin E1 (PGE1)–
induced inhibition of platelet aggregation.13,14 Platelets contain or
generate many inflammatory mediators including TXA2, platelet
activating factor (PAF), RANTES (regulated upon activation,
normal T-cell expressed and presumably secreted), histamine,
serotonin, soluble CD40 ligand (sCD40L), and growth factors.15
These mediators are released upon platelet activation and have
been associated with inflammatory lung disease in asthma.16
Therefore, endogenous platelet activation with release of proinflam-
matory mediators could play an important role in the pathogenesis
of CF lung disease, and a greater understanding of this mechanism
could lead to novel clinical interventions. Significantly, anti-
inflammatory agents known to inhibit production and release of
platelet-derived inflammatory mediators slow the progression of
lung disease in CF.17
In this study, we attempted to further elucidate platelet
function in CF and to determine if the abnormalities were due to
a plasma factor or were an intrinsic property of CF platelets. In
addition, we looked for both CFTR protein and CFTR mRNA in
platelets to determine whether the underlying CF defect in
chloride channel function could account for the platelet abnor-
malities. Finally, lipid fractions of CF and control platelets were
examined because we have previously demonstrated that CFTR-
expressing tissue from patients with CF has an imbalance in
long-chain polyunsaturated fatty acids with an excess of arachi-
donic acid (AA, a precursor to proinflammatory mediators) and
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a paucity of docosahexaenoic acid (DHA, a precursor to
anti-inflammatory mediators);18 such a fatty acid imbalance in
CF platelets could contribute to their hyperreactivity.
Patients, materials, and methods
Patient enrollment
CF patients and healthy control subjects were enrolled in this study. This study
was approved by UMass Medical School’s Committee for the Protection of
Human Subjects in Research (institutional review board [IRB]), Worcester, MA.
IRB-approved, written informed consent was obtained for all CF patients and
healthy control subjects, in accordance with the Declaration of Helsinki. All CF
patients included in the study met the CF Foundation Consensus Statement
requirements for the diagnosis of CF.19 Patients were either outpatients in their
usual state of health or inpatients receiving care for an exacerbation of their CF
(Table 1). Hospitalized patients had blood drawn within 24 to 48 hours of
admission to limit treatment effect from antibiotics or diet changes. Only one
patient was receiving steroid therapy at the time of the study (patient no. 11, Table
1). Clinical information regarding genotype, pulmonary function, and vitamin E
status of the CF patients is shown in Table 1. Neither patients nor controls
ingested antiplatelet medication (including aspirin and other nonsteroidal anti-
inflammatory drugs [NSAIDS]) for 10 days prior to blood collection. Where
appropriate,ABO and Rhesus D (RhD) blood groups of the control subjects were
matched to the relevant CF patients.
Comparison of circulating activated platelets and platelet
reactivity between CF patients and healthy controls
Circulating activated platelets and platelet reactivity in CF patients and healthy
control subjects were compared by whole-blood flow cytometric detection of
monocyte-platelet aggregates and neutrophil-platelet aggregates.20,21 Blood
samples were obtained via venipuncture from CF patients (n 18) and healthy
controls (n 18) by mixing 9 parts whole blood with 1 part 0.105 M (3.2%)
trisodium citrate. Samples were assayed within 15 minutes. Microfuge tubes
were prepared containing a mixture of HEPES-Tyrode buffer (10 mM HEPES
[N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid], 137 mM sodium chlo-
ride, 2.8 mM potassium chloride, 1 mM magnesium chloride, 12 mM sodium
carbonate, 0.4 mM sodium phosphate, 5.5 mM glucose, 0.35% wt/vol bovine
serum albumin, pH 7.4), fluorescein isothiocyanate (FITC)–conjugated anti-
CD14 (TU¨ K4; DAKO, Carpinteria, CA), phycoerythrin (PE)–conjugated anti-
CD41 (5B12; DAKO), and platelet agonist. The blood sample was added to this
reaction mixture and incubated at room temperature for 15 minutes. Final
concentrations of agonists in the reaction mixture were 1.5M thrombin receptor
activating peptide (TRAP), 0.5 or 20 M adenosine diphosphate (ADP), or no
agonist (HEPES-Tyrode buffer). After incubation, samples were fixed and
erythrocytes lysed by fluorescence-activated cell sorter (FACS) lysing solution
(Becton Dickinson, Mountain View, CA). Samples were analyzed in a FACSCali-
bur (Becton Dickinson) flow cytometer. Monocytes and neutrophils were
identified by light scatter properties and differential expression of CD14. Staining
with an irrelevant PE-conjugated mouse immunoglobulin G1–phycoerythrin
(MIgG1-RPE; DAKO) was used to set a marker to identify platelet CD41
Table 1. Clinical characteristics of cystic fibrosis patients
Patient Age, y
Vitamin E,
mg/L*
FEV1, %
predicted†
Inpatient or
outpatient‡ Genotype Platelet studies§
1 20 6.6 25 In F508/unk A
2 20 3.6 70 In F508/G542X A
3 11 16.8 92 Out F508/dF508 A
4 16 5.4 101 Out F508/G542X A
5 9 3.9 124 Out F508/dF508 A,F
6 6 5.1 118 Out F508/dF508 A,F
7 13 8.1 119 Out F508/dF508 A,F
8 10 9.7 104 Out F508/dF508 A,F
9 22 9.0 58 In F508/dF508 A
10 19 8.0 57 Out F508/N1303K A
11 17 7.0 24 Out F508/dF508 A,D,E
12 20 3.2 55 Out F508/dF508 A,D
13 15 5.8 41 In F508/dF508 A,D,E
14 26 12.7 88 Out F508/dF508 A,D
15 11 16.3 72 Out F508/W1282X A,D
16 18 10.0 58 In F508/dF508 A,D
17 22 10.5 50 Out F508/dF508 A,D
18 35 8.6 87 Out F508/C276X A,E
19 17 16.2 62 In F508/dF508 B,E
20 14 4.1 85 In F508/dF508 B
21 22 2.3 62 In F508/G542X B
22 21 7.7 54 In F508/N1303K B
23 19 2.4 69 In F508/Y1092X B
24 19 4.6 87 In F508/dF508 B, C, E
25 21 8.2 58 In R334W/unk C
26 22 5.8 85 In F508/dF508 C,E
27 22 2.9 67 In unk/unk C
28 20 6.7 77 In F508/dF508 E
29 18 13.3 92 In F508/dF508 E
30 22 8.8 71 In F508/394delTT E
31 15 13.0 68 In F508/dF508 E
32 14 unk 97 Out F508/dF508 E
unk indicates unknown.
*Measured as alpha-tocopherol. Lower limit of normal  5.5 mg/L.
†Normal: 80% to 120% of predicted.
‡Outpatients were seen for routine CF Clinic visit; inpatient were hospitalized for therapy of an exacerbation of CF.
§Studies done on each subject’s platelets: A indicates leukocyte-platelet aggregates (Figure 1); B, whole blood studies (Figures 2-3); C, washed platelet-P-selectin
measurements (Figure 4); D, inhibition of P-selectin expression by PGE1 (Figure 5); E, measurement of fatty acids (Figure 6); and F, AA and thromboxane release.
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leukocytes. Expression of platelet-specific CD41 on the surface of the leukocytes
indicated the formation of monocyte-platelet aggregates or neutrophil-platelet
aggregates. The percentage of monocyte-platelet aggregates and neutrophil-
platelet aggregates in circulating blood (ie, no exogenously added agonist) and
the reactivity of platelets to TRAP and ADP was compared for CF patients and
healthy controls by unpaired t tests.
Activation and reactivity of normal donor and CF platelets by
CF plasma
To determine if platelet activation occurred secondary to a CF plasma
constituent or as a result of an intrinsic CF platelet hyperreactivity, a plasma
crossover experiment was conducted and platelet activation and reactivity
were assessed by monocyte- and neutrophil-platelet aggregation using
whole-blood flow cytometry.20,21 Blood from CF patients and ABO
RhD-matched control subjects (n  6 pairs) was drawn into 3.2% citrate
vacuum tubes. Citrated plasma was obtained by centrifugation at 1700g for
15 minutes at room temperature. Citrated whole blood (120 L) from
healthy controls was incubated with 420 L normal or CF plasma and then,
in a parallel experiment, 120 L citrated whole blood from CF patients was
incubated with 420 L normal or CF plasma for 20 minutes at room
temperature. In analogous experiments, 420 L normal plasma was used to
resuspend Mead acid (20:3 n-9) at 3 concentrations (1, 5, or 25 M) that
were then mixed with autologous whole blood 120 L and incubated for 30
minutes at room temperature to determine if incorporation of this fatty acid
into non-CF platelets affected formation of heterotypic aggregates (n  6).
Aliquots of each mixture were added to a reaction mix consisting of
FITC-conjugated anti-CD14 (TU¨ K4), PE-conjugated anti-CD41 (5B12),
and agonist. Final concentrations of agonists in the reaction mixture were 4
or 20 M ADP, and 3 M TRAP. Samples were fixed, lysed, and analyzed
for monocyte- and neutrophil platelet aggregates as described for measure-
ment of circulating activated platelets. Matched pair-wise comparison of
means for each mixture for each agonist was achieved using 2-sided, paired
t tests.
Activation and reactivity of washed healthy donor and CF
platelets
In order to assess the activation and reactivity of CF platelets without the
influence of plasma constituents, P-selectin expression on washed platelet
preparations was determined by flow cytometry.21-24 Washed platelet
preparations of CF patients (n  4) and healthy controls (n  4) were
prepared using established methods.22,25 Briefly, platelet-rich plasma (PRP)
was prepared by centrifugation of 3.2% citrated blood samples at 150g for
15 minutes at room temperature. PRP was added to citrate wash buffer (11
mM glucose, 128 mM sodium chloride, 4.3 mM sodium phosphate
monobasic, 7.5 mM sodium phosphate, 4.8 mM sodium citrate, 2.4 mM
citric acid, 0.35% wt/vol bovine serum albumin, pH 6.5) containing apyrase
VII (1.2 U/mL; Sigma, St Louis, MO) and PGE1 (300 ng/mL; Cayman
Chemical, Ann Arbor, MI), and the mixture was centrifuged at 1200g for 10
minutes at room temperature. The platelet pellet was resuspended in this
buffer and washed twice more. The resulting platelet pellet was resus-
pended at 1.5  108/mL in HEPES-Tyrode buffer without apyrase or PGE1.
Platelets were activated with ADP (final concentrations 0, 1.25, 2.5, 5, 10,
and 20 M) for 30 minutes at room temperature, fixed, and analyzed for
surface P-selectin expression using flow cytometry.22 Platelets were identi-
fied by light scatter characteristics and the binding of an FITC-conjugated
CD61-specific monoclonal antibody (Y251; DAKO). Nonspecific binding
was determined using isotype-matched RPE-conjugated MIgG2a (DAKO),
and the expression of P-selectin on platelets was then quantified by the
binding of PE-conjugated anti-CD62P monoclonal antibody (1E3; DAKO)
to the platelet surface. For each agonist concentration, platelet mean
P-selectin fluorescence and percentage of platelets positive for P-selectin
expression were compared between CF patients and healthy controls by
unpaired t tests.
Ibuprofen and PGE1 inhibition of CF platelet activation
Citrated whole blood from CF patients and healthy donor controls (n  7)
was preincubated ex vivo with and without PGE1 (100 nM and 1 M). The
samples were then activated with 20 M TRAP or 20 M ADP. In other
experiments, whole blood (n  5) was preincubated with 50 g/mL
ibuprofen and stimulated with TRAP and ADP, 20 M U46619 (TXA2
analog), or 250 g/mL AA. Both ibuprofen- and PGE1-treated samples
were analyzed for P-selectin expression as with washed platelets.
Measurement of platelet arachidonic acid release and
thromboxane A2 production
Washed platelets from CF (n 4) and healthy donor (n 4) blood were labeled
with [3H]-arachidonic acid (0.5Ci [0.0185 MBq]/2 109 platelets/mL, 65.9 Ci
[2.4 MBq]/mmol; Perkin Elmer Life and Analytical Sciences, Boston, MA) as
previously described.26 Platelet samples were resuspended in HEPES-Tyrode
buffer, pH 7.4, and stimulated for 2 minutes with buffer or TRAP (20 M), and
the supernatants were mixed with butylated hydroxytoluene (BHT) (50 mg/mL,
3L BHT/400L sample) and citric acid (1 M, 60L/sample), then frozen until
analysis. Lipids were extracted and analyzed by thin-layer chromatography with
TXB2 (10 L of 1 mg/mL stock in ethanol) (Biomol International, Plymouth
Meeting, PA) as a standard.27
Analysis of platelets for CFTR protein and mRNA
The expression of the CFTR protein in platelets and platelet membranes
was determined by Western blot analysis. Washed platelets from both CF
patients (n  2) and healthy control subjects (n  2) were prepared with
and without cell surface biotinylation. The blots were incubated with
anti-CFTR antibodies (M3A7 and L12B4; Upstate Biotechnology, Lake
Placid, NY) and developed.28 Canine cocker-spaniel kidney cells (MDCK-1)
were used as a positive control. The presence or absence of CFTR mRNA in
platelets (and in the positive controls [leukocytes]) was determined by
reverse-transcriptase–polymerase chain reaction (RT-PCR), using estab-
lished methods.29 Total RNA was isolated and DNase treated before reverse
transcription.30 Message from 2 control housekeeping genes (GADPH and
-actin) was analyzed by real-time RT-PCR using reagent kits obtained
from Applied Biosystems (Foster City, CA).
Fatty acid analysis
Washed platelet pellets were obtained from CF patients (n  11) and
healthy control subjects (n  10). Lipid fractions of platelets were extracted
and methylated according to the method of Moser and Moser.31 Fatty acid
methyl esters were quantified via gas chromatography–mass spectrometry
as previously described.18 Total ion monitoring was performed and the mass
of fatty acids was determined by comparing areas of unknown fatty acid
methyl esters with a fixed concentration of internal standards. All speci-
mens were analyzed in a blinded fashion and assay batches included platelet
lipids from both study groups. The concentrations of fatty acids between CF
and healthy controls were compared by unpaired t tests.
Statistics
Statistical comparisons were made using paired or unpaired t tests as
appropriate. Matched comparisons (eg, before and after agonist on the same
patient, normal blood with or without CF plasma added) were made using
paired t tests. Unmatched comparisons were made using unpaired t tests.
Results
Circulating activated platelets and platelet reactivity in CF
CF patients had increased circulating activated platelets compared
with healthy controls, as measured by both monocyte-platelet
aggregates and neutrophil-platelet aggregates (Figure 1A-B “no
agonist”). Platelet activation, as determined by monocyte-platelet
aggregates and neutrophil-platelet aggregates, was greater in CF
patients compared with healthy subjects following stimulation with
1.5 M TRAP, 0.5 M ADP, and 20 M ADP (Figure 1).
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Extrinsic versus intrinsic platelet defect
Monocyte-platelet and neutrophil-platelet aggregates in CF whole blood
were higher after incubation with ABO/RhD-matched CF plasma than
after incubation with normal plasma (Figure 2A). Similarly, monocyte-
platelet and neutrophil-platelet aggregates in normal whole blood were
higher after incubation with ABO/RhD-matched CF plasma than after
incubation with normal plasma (Figure 2B). Figure 2C compares the
solid bars of Figure 2A (CF plasma  CF whole blood) with the open
bars of Figure 2B (CF plasma  normal whole blood). Figure 2C
demonstrates that when whole blood from CF and healthy subjects was
incubated in CF plasma, platelet activation (as determined by monocyte-
platelet aggregates and neutrophil-platelet aggregates) was greater in CF
blood than in normal blood. In summary, Figure 2 demonstrates that CF
plasma makes normal and CF platelets more reactive than does normal
plasma (Figure 2A-B), but that CF platelets are more reactive than
control platelets irrespective of the plasma milieu (Figure 2C).
In whole blood from healthy control subjects, monocyte- and
neutrophil-platelet aggregates were greater when incubated with
ABO/RhD-matched CF plasma than when incubated with normal
plasma, after stimulation with 4 M ADP, 20 M ADP, and 3 M
TRAP (Figure 3A).
Similarly, in CF whole blood, monocyte- and neutrophil-
platelet aggregates were greater when incubated with CF plasma
than when incubated with ABO/RhD-matched normal plasma, after
stimulation with 4 M ADP, 20 M ADP, and 3 M TRAP (Figure
3B). Thus, CF plasma increased the reactivity of both normal and
CF platelets to ADP and TRAP.
P-selectin expression of washed platelets was greater in CF
patients than in healthy control subjects after activation with
various concentrations of ADP (Figure 4). Unstimulated P-selectin
expression was slightly, though not significantly, greater in CF
platelets than controls (Figure 4). That washed, plasma-free CF
platelets were more reactive to ADP than normal platelets indicates
that the hyperreactivity of CF platelets is due in part to an intrinsic
platelet mechanism.
Effects of PGE1
The elevated P-selectin expression after agonist stimulation of CF
platelets was incompletely inhibited by 100 nM PGE1 (Figure 5,
solid bars). In contrast, normal platelets showed more complete
inhibition of agonist-induced P-selectin expression with PGE1
(Figure 5 hatched bars). There was no greater inhibition of
P-selectin expression even when using concentrations of PGE1 up
to 1 M. These results suggest that both increased cyclic adenosine
monophosphate (cAMP) levels and other factors are important in
the increased platelet surface P-selectin expression in CF.
Effect of ibuprofen on CF platelet function
Pretreatment of CF platelets with 50 g/mL ibuprofen did not
significantly decrease platelet surface P-selectin expression in
response to stimulation with ADP or TRAP (data not shown).
However, when AA was used as the agonist, pretreatment with
ibuprofen markedly inhibited P-selectin expression, as would be
expected. The platelet response to the stable TXA2 analog U46619
was unaffected by pretreatment with ibuprofen, verifying the
presence of normal TXA2 receptors on these cells.
CFTR protein and mRNA are not expressed in platelets
CFTR protein was not detected in control or CF platelet lysates or
biotinylated platelet membrane fractions using Western blot analy-
sis, but was seen in the control MDCK whole-cell lysate. CFTR
mRNA was not detected in platelet preparations from healthy
controls. CFTR message was detected in the leukocyte-positive
control samples as expected. The mRNA of 2 housekeeping genes
Figure 1. CF patients have increased circulating monocyte- and neutrophil-
platelet aggregates and increased platelet responsiveness to ADP and TRAP
compared with healthy controls. Whole blood from CF patients and healthy
controls was incubated with or without agonist and analyzed for (A) monocyte-platelet
aggregates and (B) neutrophil-platelet aggregates. Data are mean  SEM; n  18.
*P 	 .05 versus healthy controls. P 	 .01 versus healthy controls.
Figure 2. CF plasma causes activation of normal and
CF platelets. (A) Monocyte- and neutrophil-platelet ag-
gregates in CF whole blood after incubation in ABO/RhD-
matched CF or normal control plasma. (B) Monocyte-
and neutrophil-platelet aggregates in normal whole blood
after incubation in ABO/RhD-matched CF or normal
control plasma. (C) Comparison of the solid bars of panel
A (CF plasma  CF whole blood) with the open bars of
panel B (CF plasma  normal whole blood). Panel C
demonstrates that when whole blood from CF and healthy
subjects was incubated in CF plasma, platelet activation
(as determined by monocyte-platelet and neutrophil-
platelet aggregates) was greater in CF blood than in
normal blood. Data are mean  SEM; n  6. *P 	 .05
versus normal plasma or whole blood.
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(GADPH and -actin) was detected in all platelet samples,
confirming the integrity of the platelet RNA.
Platelet fatty acid content
Analysis of washed platelet pellets for fatty acid pools showed a
significant increase in 20:3 n-9 (Mead acid) levels in CF platelets
compared with healthy control subject platelets (P  .017, Figure
6) and plasma (P  .006, not shown). There was also an increase in
22:5 n-6 in CF platelets compared with healthy controls (P  .012)
(Figure 6). However, CF platelets were not significantly different
from control platelets with regard to concentrations of AA (20:4
n-6), DHA (22:6 n-3), and the AA/DHA ratio (Figure 6).
Arachidonic acid release and Mead acid effect
Not only was total AA not different between CF and control
platelets (Figure 6), there was no difference in AA release or
synthesis of the AA metabolite TXA2 as demonstrated by use of
[3H]-AA (results not shown). Addition of Mead acid (20:3, n-9) to
normal platelets did not increase the formation of monocyte-
platelet or neutrophil-platelet aggregates (results not shown).
No correlation between platelet activation and vitamin E status
or pulmonary function
There was no correlation between any of the measurements of
platelet activation and vitamin E status or pulmonary function as
measured by the percent of predicted forced expiratory volume in
the first second of expiration (FEV1%) in the CF patients.
Discussion
The conclusions of this study are (1) CF patients have an increase
in circulating activated platelets and platelet reactivity, as deter-
mined by monocyte-platelet aggregation, neutrophil-platelet aggre-
gation, and platelet surface P-selectin; (2) this increased platelet
activation in CF is the result of both a plasma factor(s) and an
intrinsic platelet mechanism via cAMP/adenylate cyclase (as
evidenced by the results with PGE1), but not via platelet CFTR.
In this study, we demonstrated that CF patients have increased
numbers of circulating activated platelets compared with healthy control
subjects, as measured by monocyte-platelet and neutrophil-platelet
aggregates (Figure 1). We have previously demonstrated that these
heterotypic aggregates are very sensitive markers of platelet activation.32
In addition, whole blood studies showed that CF platelets had greater
aggregability with monocytes and neutrophils in response to agonists
than did control platelets (Figure 1). CF plasma caused activation of
normal and CF platelets (Figure 2), but the activation was greater in the
CF platelets than in normal platelets. CF plasma also increased the
reactivity of normal and CF platelets to ADP and TRAP (Figure 3).
Furthermore, there was an increased surface expression of P-selectin in
CF washed platelet preparations compared with washed normal platelets
(Figure 4). Taken together, these experiments demonstrate that the
increased platelet activation in CF is the result of both an intrinsic
platelet mechanism and plasma factors. Even in well, young CF patients
with normal pulmonary function there is an abnormality in platelet
function. Our findings are consistent with previous work that has shown
increased platelet aggregation and/or markers of platelet activation in CF
patients.10-12,33-35 Thus, excessive platelet activation is present in CF and
may contribute significantly to the lung disease seen in this disorder.
Interestingly, our results do not support the earlier findings of
increased TXA2 release from CF platelets.10 The finding of increased
urinary TXB2 by Ciabattoni et al11 would support a hypothesis that
platelet activation contributes directly to lung damage. The results of our
study suggest that there is a source other than platelets for the urinary
thromboxane, as has been previously suggested.36 However, we did
Figure 3. CF plasma increases the reactivity of normal and CF platelets to ADP
and TRAP. (A) Monocyte- and neutrophil-platelet aggregates in normal control whole
blood incubated with CF plasma or ABO/RhD-matched normal plasma and then
stimulated with agonist. (B) Monocyte- and neutrophil-platelet aggregates in CF
whole blood incubated with CF plasma or ABO/RhD-matched normal plasma and
then stimulated with agonist. Data are mean  SEM; n  6. *P 	 .05 versus normal
plasma. P 	 .01 versus normal plasma.
Figure 4. Washed CF platelets are more reactive to ADP than normal platelets
as measured by P-selectin expression. Percentage of CF and normal washed
platelets expressing P-selectin with and without stimulation by ADP. Data are mean
SEM; n  4. *P 	 .05 versus normal platelets.
Figure 5. CF platelet hyperreactivity is incompletely inhibited by PGE1. Percent-
age of CF and normal platelets in whole blood expressing P-selectin after stimulation
with TRAP or ADP in the absence (A) or presence (B) of 100 nM PGE1. Data are
mean  SEM; n  7. *P 	 .05 versus healthy controls. P 	 .01 versus healthy
controls.
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confirm that the platelets from CF patients are hyperreactive compared
with control platelets. The metabolic basis and downstream conse-
quences of the platelet hyperreactivity remain to be elucidated.
Others13,14 have shown an incomplete inhibition of platelet
aggregation by PGE1, and we observed a decreased response to
PGE1 inhibition of surface P-selectin expression in CF compared
with control platelets. An absence of the cAMP-regulated chloride
channel, CFTR, in CF platelets could explain these findings.
However, we found neither message for CFTR nor CFTR protein
itself in normal donor platelets. Therefore, the intrinsic abnormality
in CF platelets must be due to a non-CFTR cAMP-regulated
platelet chloride channel or to a CFTR-related abnormality that is
expressed in megakaryocytes but not in platelets.
We have reported abnormalities in fatty acids in CFTR expressing
tissue that could affect inflammation in CF patients; that is, epithelial
cells have an abnormal ratio of omega-6 to omega-3 fatty acids,
specifically an increase in theAA/DHAratio.18 Such an imbalance could
lead to an increase in proinflammatory derivatives of AA and a paucity
of anti-inflammatory DHA metabolites.37 Consistent with our inability
to find evidence of CFTR expression in platelets, however, platelets
from CF patients did not differ significantly from control platelets with
regard to AA or DHA (Figure 6). Thus, we cannot ascribe the increased
intrinsic platelet reactivity in CF to an abnormality in platelet AA/DHA
balance. However, this imbalance is present in plasma18,38 and could
lead to platelet activation from increased circulating AA metabolites
(consistent with the previously reported increased urinary thromboxane
in CF11). Recently, CF patients and CF knock-out mice have been
shown to be deficient in the anti-inflammatory lipoxin family of
mediators.39 The proposed imbalance in CF pro- and anti-inflammatory
mediators could favor platelet activation, even if the platelets themselves
do not intrinsically release excess thromboxane.
Further fatty acid analysis revealed an increase in the terminal n-6
fatty acid (22:5 n-6) in CF platelets (Figure 6). Accumulation of this
long-chain, polyunsaturated fatty acid may competitively inhibit the
generation of DHA at the level of the DHA precursor, 22:5 n-3. We also
observed an increase in Mead acid (20:3 n-9) in CF platelets (Figure 6)
and plasma (not shown). Lagarde et al40 showed that Mead acid is
metabolized by a platelet-derived lipoxygenase to an end product with
PGE2-like activity that enhances platelet aggregation and that loading
normal platelets with Mead acid enhances their aggregability.41 How-
ever, when we incubated platelets with 3 different concentrations of
Mead acid in the presence or absence of a platelet agonist, we did not
observe any increase in whole blood heterotypic aggregates. In sum-
mary, an intrinsic fatty acid abnormality is present in CF platelets and it
is possible that the increase in platelet activation observed is due to a
manifestation of this abnormality, but excess Mead acid alone does not
lead to increased platelet-leukocyte aggregates.
There are a number of potential plasma-mediated explanations
for platelet hyperreactivity in CF. The imbalance in omega-3 and
omega-6 fatty acids seen in CF serum may favor inflammation, as
may an increase in plasma levels of sCD40L.34 In addition,
approximately 90% of CF patients have pancreatic insufficiency
and are at risk for malabsorption of fat-soluble vitamins,9 leading
some to postulate a relationship between low levels of the
antioxidant vitamin E and increased platelet activation.11,33 Our
results do not support the concept that increased platelet activation
in CF is a consequence of a nutritional depletion of vitamin E, as
we saw no correlation between vitamin E status and platelet
activation. There are other oxidant stresses in CF (including a
purported depletion of glutathione, an increase in reactive oxygen
species from neutrophils, and generation of isoprostanes from
long-chain polyunsaturated fatty acids by the action of H2O2)42,43
that may contribute to platelet activation.
CFTR dysfunction, as seen in CF, has been associated with an
elevation in plasma ATP.44 On balance, ATP is probably an agonist
of platelet aggregation and activation in vivo.45 Thus, increased
platelet activation may be a direct consequence of the basic
molecular defect in CFTR due to disturbances in fatty acid
metabolism or due to increased plasma ATP concentrations even
though CFTR is not expressed in platelets.
The pulmonary inflammatory response in CF patients is exagger-
ated compared with healthy individuals, with evidence of airway
inflammation as early as 4 weeks of age.46 Konstan et al17 showed
that high-dose ibuprofen led to a slowing of the loss of lung
function when used over 4 years in CF patients. Serum levels of
ibuprofen in this study were high enough to inhibit the migration,
adherence, swelling, and aggregation of neutrophils.17,47 Many CF
clinicians have avoided using such high doses of ibuprofen because
of the need to monitor serum levels of the drug and because of
concerns about the potential adverse effects of this high-dose
regimen. Thus, in 2003 only about 5% of patients cared for at CF
Foundation–accredited centers received high-dose ibuprofen.9 If
the benefit observed in the NSAID study of CF patients was due,
even in part, to inhibition of platelet activation rather than
decreased neutrophil function, then a lower dose regimen of
NSAID might be effective and would be more appealing to
clinicians and patients. Furthermore, aspirin and/or clopidogrel,
which are stronger antiplatelet drugs than NSAIDs, may have
greater beneficial effects than NSAIDs in patients with CF.
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Figure 6. Platelet fatty acid content. There is no
difference between CF and control platelets with regard
to AA, DHA, or their ratio (A-B); however, CF platelets
have increased Mead acid (20:3 n-9) and 22:5 n-6 fatty
acid concentrations compared with control platelets (C).
Data are mean  SEM; n  11 CF patients and n  10
healthy controls. *P 	 .05 versus control platelets.
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